482 results on '"PETERSSON, MAGNUS"'
Search Results
2. Cold winds in the north: Three perspectives on the impact of Russia's war in Ukraine on security and international relations in the Arctic
3. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial
4. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
5. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
6. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
7. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status
8. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER
9. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
10. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
11. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
12. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
13. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
14. Conclusion
15. Introduction. Pax Suecia, 1814–2020
16. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
17. Abstract 18437: Efficacy and Safety of Dapagliflozin in Patients With Heart Failure and Previous Myocardial Infarction
18. Abstract 18170: Microvascular Complications of Type 2 Diabetes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction in the DELIVER Trial
19. Abstract 13678: Initial Decline in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Insights From DELIVER
20. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER
21. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
22. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
23. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial
24. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure
25. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction
26. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
27. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial
28. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial
29. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER
30. Small states and autonomous systems: the Scandinavian case
31. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF:The DELIVER Trial
32. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin:A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
33. Sweden, Finland, and the Defence of the Nordic-Baltic Region—Ways of British Leadership
34. ‘The Allied Partner’: Sweden and NATO Through the Realist–Idealist Lens
35. Small state survival strategies and the arms trade
36. Sex Differences in Heart Failure With Improved Ejection Fraction
37. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
38. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials
39. Contemporary Use and Implications of Beta-blockers in Patients with HFmrEF or HFpEF: the DELIVER Trial
40. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure
41. Weak party escalation: An underestimated strategy for small states?
42. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
43. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial
44. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials
45. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
46. A Europe in crisis
47. A reluctant ally
48. Conclusion – a way forward
49. NATO and the Crisis in the International Order
50. Introduction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.